Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenoperidine is a synthetic opioid analgesic structurally related to pethidine (meperidine), developed by replacing the N-methyl group of pethidine with a phenyl propanol chain[1][3][7]. It is characterized by high potency (20–200 times that of pethidine), rapid onset, intense peak effect, and short duration of action[1][3][7]. Phenoperidine acts as a typical morphine-like analgesic and is used primarily in general anesthesia for its strong pain-relieving properties[1][3][7]. It acts as an **agonist of the Mu-type opioid receptor**. It is metabolized in the liver—partly to norpethidine—and excreted via bile and urine[3][7]. Its clinical use has declined but it remains historically significant as a precursor in the development of neuroleptic drugs such as haloperidol and droperidol[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenoperidine.